Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kossak, B. D.
Right arrow Articles by Tonsgard, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kossak, B. D.
Right arrow Articles by Tonsgard, J. H.
NEUROLOGY 1993;43:2362
© 1993 American Academy of Neurology

Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine

B. D. Kossak, MD, E. Schmidt-Sommerfeld, MD, D. A. Schoeller, PhD, P. Rinaldo, MD, D. Penn, MD and J. H. Tonsgard, MD

Departments of Neurology (Drs Kossak and Tonsgard), Pediatrics (Drs Schmidt-Sommerfeld, Penn, and Tonsgard), and Medicinci (Dr Schoeller), and the Joseph Kennedy Mental Retardation Center, The University of Chicago. Chicago, IL; and the Department of Genetics (Dr. Rinaldo), Yale University, New Haven, CT

Fatty acid oxidation was studied in 12 patients (aged 3 to 19 years) receiving valproic acid (VPA), predominantly as monotherapy, before and after 1 month of L-carnitine supplementation (50 mg/kg/day po) in order to determine whether L-carnitine plays a role in preventing the hepatotoxic effects of this drug. Five of these patients were also studied prior to VPA treatment. Only one patient taking VPA had an abnormally low plasma free carnitine. Acyl-/free carnitine ratios were elevated in five patients on VPA and normalized after L-carnithe supplementation. Mean plasma concentrations of free fatty acids, ß-OH-butyrate, and cumulative excretion of 13CO2 after administration of 1-13C-octanoic acid were not changed by VPA or L-carnitine treatment. Urinary dicarboxylic acids, acylglycines, and octanoylcarnitine were elevated during VPA therapy and unaltered by L-carnitine. These results suggest that, in patients at low risk for VPA-induced hepatotoxicity (patients aged >2 years and taking VPA as monotherapy), VPA causes metabolic abnormalities resembling those found in inborn errors of mitochondria1 ß-oxidation which are not corrected by L-carnitine.

Address correspondence and reprint requests to Dr. Eberhard Schmidt-Sommerfeld, Department of Prdiatrics. Louisiana State University, 1542 Tulane Avenue, New Orleans, LA 70112–2822

Supported by the Children's Research Foundation of the University of Chicago and N1H grant DK 26678 Received November 16, 1992 Accepted for publication in final form March 31, 1993




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
E. P. Brass
Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man
Pharmacol. Rev., December 1, 2002; 54(4): 589 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
O A F Bodamer and D Halliday
Uses of stable isotopes in clinical diagnosis and research in the paediatric population
Arch. Dis. Child., May 1, 2001; 84(5): 444 - 448.
[Full Text]

Home page
 J Child NeurolHome page
P. R. Borum
Carnitine in Neonatal Nutrition
J Child Neurol, November 1, 1995; 10(2_suppl): 2S25 - 2S31.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
D. L. Coulter
Carnitine Deficiency in Epilepsy: Risk Factors and Treatment
J Child Neurol, November 1, 1995; 10(2_suppl): 2S32 - 2S39.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by AAN Enterprises, Inc.